Late gastrointestinal toxicity after radiation for prostate cancer

Sharon H. Giordano, Andrew Lee, Yong Fang Kuo, Jean Freeman, James Goodwin

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

BACKGROUND. The current study was designed to determine rates and predictors of late, lower gastrointestinal toxicity after radiation therapy in a population-based cohort of older men with prostate cancer. METHODS. The study population consisted of men with localized or regional stage prostate cancer who were age ≥66 years and were diagnosed between 1992 and 1999 who were identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Gastrointestinal diagnoses were ascertained through claims from 6 to 60 months after diagnosis. The relative rates of diagnoses in the radiation group versus the nonradiation group were used as a means of estimating toxicity from radiotherapy. Cox modeling was used to determine factors associated with gastrointestinal diagnoses. RESULTS. A total of 57,955 men were included, 24,130 of whom were treated with radiation therapy. Among patients with 5 years of follow-up, the rates of gastrointestinal diagnoses were 19.4% higher in irradiated patients than among patients who did not have local therapy. Hemorrhage was the most common diagnosis, and was increased by 18.9% among patients treated with radiation (39.6% of irradiated patients vs. comparison rates of 18.2% in patients treated with radical prostatectomy and 20.7% in patients with no local therapy). Diagnostic lower endoscopies were performed in an additional 20.9% of men (32.4% of men treated with radiation vs. 12.7% of men who underwent prostatectomy). In all, 4.4% of irradiated men were hospitalized with a gastrointestinal diagnosis versus comparison rates of 3.2% among men with no local therapy. In multivariate models, increasing patient age, hormonal therapy, comorbidity, diabetes, peripheral vascular disease, and hemorrhoids were all associated with gastrointestinal diagnoses consistent with toxicity, whereas tumor stage and grade were not predictors. CONCLUSIONS. Lower gastrointestinal toxicity after radiation therapy for prostate cancer continues for at least 5 years and may be more common than previously reported.

Original languageEnglish (US)
Pages (from-to)423-432
Number of pages10
JournalCancer
Volume107
Issue number2
DOIs
StatePublished - Jul 15 2006

Fingerprint

Prostatic Neoplasms
Radiation
Radiotherapy
Prostatectomy
Hemorrhoids
Peripheral Vascular Diseases
Therapeutics
Medicare
Population
Endoscopy
Comorbidity
Epidemiology
Databases
Hemorrhage
Neoplasms

Keywords

  • Gastrointestinal toxicity
  • Prostate cancer
  • Radiation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Late gastrointestinal toxicity after radiation for prostate cancer. / Giordano, Sharon H.; Lee, Andrew; Kuo, Yong Fang; Freeman, Jean; Goodwin, James.

In: Cancer, Vol. 107, No. 2, 15.07.2006, p. 423-432.

Research output: Contribution to journalArticle

Giordano, Sharon H. ; Lee, Andrew ; Kuo, Yong Fang ; Freeman, Jean ; Goodwin, James. / Late gastrointestinal toxicity after radiation for prostate cancer. In: Cancer. 2006 ; Vol. 107, No. 2. pp. 423-432.
@article{727803ee356b420fac4090e0060d4ecf,
title = "Late gastrointestinal toxicity after radiation for prostate cancer",
abstract = "BACKGROUND. The current study was designed to determine rates and predictors of late, lower gastrointestinal toxicity after radiation therapy in a population-based cohort of older men with prostate cancer. METHODS. The study population consisted of men with localized or regional stage prostate cancer who were age ≥66 years and were diagnosed between 1992 and 1999 who were identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Gastrointestinal diagnoses were ascertained through claims from 6 to 60 months after diagnosis. The relative rates of diagnoses in the radiation group versus the nonradiation group were used as a means of estimating toxicity from radiotherapy. Cox modeling was used to determine factors associated with gastrointestinal diagnoses. RESULTS. A total of 57,955 men were included, 24,130 of whom were treated with radiation therapy. Among patients with 5 years of follow-up, the rates of gastrointestinal diagnoses were 19.4{\%} higher in irradiated patients than among patients who did not have local therapy. Hemorrhage was the most common diagnosis, and was increased by 18.9{\%} among patients treated with radiation (39.6{\%} of irradiated patients vs. comparison rates of 18.2{\%} in patients treated with radical prostatectomy and 20.7{\%} in patients with no local therapy). Diagnostic lower endoscopies were performed in an additional 20.9{\%} of men (32.4{\%} of men treated with radiation vs. 12.7{\%} of men who underwent prostatectomy). In all, 4.4{\%} of irradiated men were hospitalized with a gastrointestinal diagnosis versus comparison rates of 3.2{\%} among men with no local therapy. In multivariate models, increasing patient age, hormonal therapy, comorbidity, diabetes, peripheral vascular disease, and hemorrhoids were all associated with gastrointestinal diagnoses consistent with toxicity, whereas tumor stage and grade were not predictors. CONCLUSIONS. Lower gastrointestinal toxicity after radiation therapy for prostate cancer continues for at least 5 years and may be more common than previously reported.",
keywords = "Gastrointestinal toxicity, Prostate cancer, Radiation",
author = "Giordano, {Sharon H.} and Andrew Lee and Kuo, {Yong Fang} and Jean Freeman and James Goodwin",
year = "2006",
month = "7",
day = "15",
doi = "10.1002/cncr.21999",
language = "English (US)",
volume = "107",
pages = "423--432",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Late gastrointestinal toxicity after radiation for prostate cancer

AU - Giordano, Sharon H.

AU - Lee, Andrew

AU - Kuo, Yong Fang

AU - Freeman, Jean

AU - Goodwin, James

PY - 2006/7/15

Y1 - 2006/7/15

N2 - BACKGROUND. The current study was designed to determine rates and predictors of late, lower gastrointestinal toxicity after radiation therapy in a population-based cohort of older men with prostate cancer. METHODS. The study population consisted of men with localized or regional stage prostate cancer who were age ≥66 years and were diagnosed between 1992 and 1999 who were identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Gastrointestinal diagnoses were ascertained through claims from 6 to 60 months after diagnosis. The relative rates of diagnoses in the radiation group versus the nonradiation group were used as a means of estimating toxicity from radiotherapy. Cox modeling was used to determine factors associated with gastrointestinal diagnoses. RESULTS. A total of 57,955 men were included, 24,130 of whom were treated with radiation therapy. Among patients with 5 years of follow-up, the rates of gastrointestinal diagnoses were 19.4% higher in irradiated patients than among patients who did not have local therapy. Hemorrhage was the most common diagnosis, and was increased by 18.9% among patients treated with radiation (39.6% of irradiated patients vs. comparison rates of 18.2% in patients treated with radical prostatectomy and 20.7% in patients with no local therapy). Diagnostic lower endoscopies were performed in an additional 20.9% of men (32.4% of men treated with radiation vs. 12.7% of men who underwent prostatectomy). In all, 4.4% of irradiated men were hospitalized with a gastrointestinal diagnosis versus comparison rates of 3.2% among men with no local therapy. In multivariate models, increasing patient age, hormonal therapy, comorbidity, diabetes, peripheral vascular disease, and hemorrhoids were all associated with gastrointestinal diagnoses consistent with toxicity, whereas tumor stage and grade were not predictors. CONCLUSIONS. Lower gastrointestinal toxicity after radiation therapy for prostate cancer continues for at least 5 years and may be more common than previously reported.

AB - BACKGROUND. The current study was designed to determine rates and predictors of late, lower gastrointestinal toxicity after radiation therapy in a population-based cohort of older men with prostate cancer. METHODS. The study population consisted of men with localized or regional stage prostate cancer who were age ≥66 years and were diagnosed between 1992 and 1999 who were identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Gastrointestinal diagnoses were ascertained through claims from 6 to 60 months after diagnosis. The relative rates of diagnoses in the radiation group versus the nonradiation group were used as a means of estimating toxicity from radiotherapy. Cox modeling was used to determine factors associated with gastrointestinal diagnoses. RESULTS. A total of 57,955 men were included, 24,130 of whom were treated with radiation therapy. Among patients with 5 years of follow-up, the rates of gastrointestinal diagnoses were 19.4% higher in irradiated patients than among patients who did not have local therapy. Hemorrhage was the most common diagnosis, and was increased by 18.9% among patients treated with radiation (39.6% of irradiated patients vs. comparison rates of 18.2% in patients treated with radical prostatectomy and 20.7% in patients with no local therapy). Diagnostic lower endoscopies were performed in an additional 20.9% of men (32.4% of men treated with radiation vs. 12.7% of men who underwent prostatectomy). In all, 4.4% of irradiated men were hospitalized with a gastrointestinal diagnosis versus comparison rates of 3.2% among men with no local therapy. In multivariate models, increasing patient age, hormonal therapy, comorbidity, diabetes, peripheral vascular disease, and hemorrhoids were all associated with gastrointestinal diagnoses consistent with toxicity, whereas tumor stage and grade were not predictors. CONCLUSIONS. Lower gastrointestinal toxicity after radiation therapy for prostate cancer continues for at least 5 years and may be more common than previously reported.

KW - Gastrointestinal toxicity

KW - Prostate cancer

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=33745839859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745839859&partnerID=8YFLogxK

U2 - 10.1002/cncr.21999

DO - 10.1002/cncr.21999

M3 - Article

VL - 107

SP - 423

EP - 432

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -